Otsuka Pharmaceutical Europe Ltd Withdraws Its Application For An Extension Of Indication For Abilify (aripiprazole), Europe

Links shared publicly online about this topic.

  • 1,589
    total visits

Otsuka Pharmaceutical Europe Ltd Withdraws Its Application For An Extension Of Indication For Abilify (aripiprazole), Europe

medicalnewstoday.com —

The european medicines agency has been formally notified by otsuka pharmaceutical europe ltd of its decision to withdraw its application for an extension of indication for the centrally authorised

View full resource at medicalnewstoday.com

Tags: Bipolar Disorder Medication, Schizophrenia Medication, Antipsychotic Medication, Pharma, Abilify

  • Share

Most Recently Shared on November 20, 2009 at 11:42 am By:

mnt_psychology MNT Psychology News

Otsuka Pharmaceutical Europe Ltd Withdraws Its Application For An Extension Of Indication For Abilify (aripipra.. http://bit.ly/1QCH4R

2 years ago...

Reply

Retweet

Favorite

Also Shared By:

MNT Mental Health MNT Mental Health

Advertisement